BioXcel Therapeutics, Inc. is a New Haven, Connecticut-headquartered clinical-stage biopharmaceutical company focused on neuroscience, with the Company's lead commercial product IGALMI® (dexmedetomidine) sublingual film approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, and the pipeline including BXCL501 (for agitation in Alzheimer's dementia, TRANQUILITY program) and BXCL701 (immuno-oncology, SERENITY program). For the second quarter ended June 30, 2026, the Company generated net product revenue of $182 thousand (up from $120 thousand in Q2 2025), with an accumulated deficit of $747.5 million (up from $720.1 million at December 31, 2025). The net loss for Q2 2026 was $14.7 million ($(0.49) per share on 30.3 million weighted average shares, up from 7.8 million in Q2 2025 reflecting the March 2025 offering and share count changes). Research and development expenses of $3.2 million were down significantly from $10.3 million in Q2 2025, while selling, general, and administrative expenses of $7.2 million were up from $5.6 million. Cash and equivalents of $28.8 million at June 30, 2026 were down from $44.9 million at year-end 2025. The Company entered into a Twelfth Amendment to its credit agreement with Oaktree (August 10, 2026) requiring definitive agreements for repayment or alternative capital solutions by August 21, 2026, with minimum liquidity covenant reduced to $3.0 million from $6.25 million.
The investment thesis rests on three variables. The IGALMI commercial traction and revenue inflection is the load-bearing commercial variable, with Q2 2026 net product revenue of only $182 thousand (up 52% from $120 thousand but still minimal) and the strategic intent to drive adoption in the emergency department and inpatient psychiatric settings for acute agitation in schizophrenia/bipolar, and the market will track the quarterly prescription trends and formulary access as real-time indicators. The liquidity runway and capital solutions execution is the load-bearing financial variable, with cash of $28.8 million at June 30, 2026, the Oaktree credit facility amendment requiring a capital solution by August 21, 2026, minimum liquidity covenant of $3.0 million, and the strategic intent to execute a financing, partnership, or asset monetization to extend the runway, and the market will track the capital solution announcement as a binary catalyst. The BXCL501 (TRANQUILITY) and BXCL701 (SERENITY) pipeline optionality is the load-bearing pipeline variable, with the TRANQUILITY program for agitation in Alzheimer's dementia and the SERENITY program in immuno-oncology representing the pipeline upside beyond IGALMI, and the strategic intent is to advance the programs while managing the R&D spend within the liquidity constraints.